



## CLINICAL FEATURES

Flare features	Assessment	Acute illness
<ul style="list-style-type: none"> <li>Mild: BO 1-3x/day ± blood and no systemic symptoms</li> <li>Moderate: BO 4-6x/day with blood and no systemic symptoms</li> <li>Severe: BO &gt;6x/day with blood, fever, tachycardia, low BP</li> </ul>	<ul style="list-style-type: none"> <li>Check pulse, temperature, BP</li> <li>Abdominal examination – masses, peritonitis</li> <li>Blood tests: FBC, U&amp;E, ESR, CRP</li> <li>Stool: faecal calprotectin ± stool culture (don't wait for result before treating)</li> <li>Seek advice from IBD team</li> </ul>	<ul style="list-style-type: none"> <li>Risk of rapid decompensation</li> <li>Acute severe colitis: BO &gt;6x/day with blood plus one or more of: fever &gt;37.8°C, pulse &gt;90bpm, Hb &lt;105 g/L or CRP &gt;30 mg/L – admit to medical team as risk of sepsis or acute kidney injury</li> <li>Abdominal mass – abscess potential in Crohn's disease – acute surgical referral</li> </ul>

## INITIAL TREATMENT

UC: left sided/pancolitis	UC: proctitis	Crohn's disease
<ul style="list-style-type: none"> <li>Increase oral mesalazine to maximum dose (varies by brand)</li> <li>Also offer rectal mesalazine</li> <li>Consider locally acting oral agents (Cortiment 9mg od for up to 8/52 or Clipper 5mg od for 28 days)</li> <li>If no response consider oral prednisolone 40mg od for 7 days then reduce by 5mg/week over 8 weeks (total 252 tablets)</li> </ul>	<ul style="list-style-type: none"> <li>Rectal therapy: mesalazine (Salofalk suppository 1g nocte, Octasa 1g suppository nocte, or Pentasa 1g suppository nocte)</li> </ul>	<ul style="list-style-type: none"> <li>Risk of severe systemic illness and abscesses more common. Do not initiate or change treatment in primary care unless specified on the personal care plan</li> <li>Discuss with local IBD team</li> <li>Enteral nutrition may be first line in children (specialist decision)</li> </ul>

## LONGER TERM

Chronic condition	Personalised care plan	Steroids
<ul style="list-style-type: none"> <li>Incurable relapsing/remitting condition. Up to 50% of IBD patients have a relapse/year</li> <li>Initial self-care strategies: diet, lifestyle, avoiding NSAIDs, psychological support</li> <li>Encourage lifetime compliance</li> </ul>	<ul style="list-style-type: none"> <li>Created by patient and specialist team</li> <li>Used to guide self-management and treatment</li> <li>Contact details for IBD advice line or local service</li> <li>Cancer risk assessment</li> </ul>	<ul style="list-style-type: none"> <li>Limit steroid quantities issued: risk of stockpiling and self-treatment</li> <li>Remember steroid card and sick day rules</li> <li>Remember gastrointestinal and bone protection when required</li> </ul>

## COMPLICATIONS

Complications of flare	Side effects of treatment	Gastroenterology review
<ul style="list-style-type: none"> <li>Fistulas</li> <li>Abscesses</li> <li>Perforation</li> <li>Obstruction</li> <li>Anaemia</li> </ul>	<ul style="list-style-type: none"> <li>Steroids: calc/VitD; consider bisphosphonate if patient &gt;65, or osteopenia/osteoporosis</li> <li>Adrenal suppression</li> <li>Mesalazine: agranulocytosis (rare)</li> </ul>	<ul style="list-style-type: none"> <li>&gt;1 steroid Rx per year: escalate for steroid-sparing treatment review if daily dose can't be reduced below 15mg prednisolone (or equivalent) or relapse occurs within six weeks of stopping steroids</li> </ul>